News
Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...
Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...
Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...
5h
Zacks.com on MSNLLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
Users of weight loss drugs such as Wegovy and Mounjaro, along with those who use type 2 diabetes drug Ozempic for weight loss ...
Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, ...
A daily pill that works like Ozempic can help slimmers lose an average of two stone, trials have found. The study of ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results